Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller’s Diarrhoea


The purpose of this study is to prove the non-inferiority of Rifamycin SV-MMX® versus Ciprofloxacin for the treatment of adults with traveller's diarrhoea.

Full Title of Study: “A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy and Safety of Oral Daily Rifamycin SV-MMX® 400 mg b.i.d. vs. Ciprofloxacin 500 mg b.i.d. in the Treatment of Acute Infectious Diarrhoea in Travellers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 2016


  • Drug: Rifamycin SV-MMX®
    • 2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
  • Drug: Ciprofloxacin
    • 1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.

Arms, Groups and Cohorts

  • Experimental: Group A
    • Rifamycin SV-MMX® 200 mg tablets
  • Active Comparator: Group B
    • Ciprofloxacin 500 mg capsules

Clinical Trial Outcome Measures

Primary Measures

  • Time to Last Unformed Stool (TLUS)
    • Time Frame: 5 days
    • Time to Last Unformed Stool (TLUS), defined as the interval in hours between the first dose of study drug and the last unformed stool passed, after which clinical cure was declared.

Secondary Measures

  • Number of Patients With Clinical Cure
    • Time Frame: 5 days
    • Clinical Cure Rate: 24-hour period with no clinical symptoms except mild flatulence, no fever, no watery stools and no more than 2 soft stools OR 48-hour period with no stools or only formed stools, and no fever, with our without symptoms of enteric infection.

Participating in This Clinical Trial

Inclusion Criteria

  • Signed informed consent, – Men or women between 18 and 85 years of age, – History of arriving from their country of residence in the industrialized part of the world within the past 4 weeks, – Presenting with acute infectious diarrhoea (defined as at least 3 unformed, watery or soft stools accompanied by symptoms within 24 hours preceding randomisation with duration of illness ≤ 72 hours), – Presence of one or more signs or symptoms of enteric infection (moderate to severe gas/flatulence, nausea, vomiting, abdominal cramps or pain, rectal tenesmus, fecal urgency), – Women of childbearing potential had to apply during the entire duration of the study a highly effective method of birth control Exclusion Criteria:
  • Residency in any country with high incidence rate of TD within the past 6 months, – Fever (defined as a body (oral) temperature >100.4°F or 38.0°C; antipyretic medication should not have been administered in the 6 hours prior to this assessment), – Known or suspected infection with non-bacterial pathogen, – Presence of diarrhoea of >72 hours duration, – Presence of grossly bloody stool, – Presence of moderate or severe dehydration (i.e. symptoms of hypovolemia such as orthostatic hypotension, dizziness or wrinkling of skin), – History of inflammatory bowel disease or celiac disease,
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: 85 Years

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Dr. Falk Pharma GmbH
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Professor Robert Steffen, M. D., Principal Investigator, University of Zurich, Switzerland

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.